Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
 
Table of Contents

On an intent-to-treat basis, Excalia demonstrated in this trial mean weight loss of 5.2% from baseline at 16 weeks, compared to 4.3% for zonisamide alone. On a completers analysis, Excalia patients demonstrated mean weight loss of 8.3% from baseline 16 weeks after the start of treatment, compared to 5.7% for zonisamide alone. At 24 weeks, the advantage of Excalia treatment in weight loss became more apparent. For the intent-to-treat and completer populations, the results at 24 weeks were as follows:
 
Excalia Phase II Mean Weight Loss at 24 Weeks
Intent-to-Treat Population
 
(GRAPH)
 
 *  Calculated on the basis of adjusted least-squares mean methodology.
 
  (1)  Placebo and bupropion monotherapy groups represent patients from our Contrave Phase II clinical trial, which we consider comparative due to the similarity of clinical trial protocols and overlapping clinical trial sites. Placebo data represents results at 16 weeks, as the placebo arm was discontinued at that point.
 
Excalia Phase II Mean Weight Loss at 24 Weeks
Completer Population
 
(GRAPH)

(footnotes on following page)


72